OncoMatch/Clinical Trials/NCT06623201
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
Is NCT06623201 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including aminolevulinic acid HCL (ALA) and BLU-U device model 4170E for basal cell carcinoma (bcc).
Treatment: aminolevulinic acid HCL (ALA) · BLU-U device model 4170E — This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions. Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Cannot have received: systemic photosensitizer
Subjects previously treated with a systemic photosensitizer within 4 months of screening date.
Cannot have received: hedgehog pathway inhibitor
hedgehog pathway inhibitor...within 6 months before the baseline visit
Cannot have received: biologics
biologics...within 6 months before the baseline visit
Cannot have received: chemotherapy
chemotherapy...within 6 months before the baseline visit
Cannot have received: topical chemotherapy (Imiquimod, fluorouracil)
topical chemotherapy agents including Imiquimod, fluorouracil to the selected treatment lesion sites within 3 weeks
Cannot have received: photodynamic therapy
Currently undergoing treatment with photodynamic therapy within 3 weeks before baseline visit.
Lab requirements
Blood counts
Within normal limit hematopoietic capacity. Values outside those limits may be allowed at the discretion of the PI, if not clinically significant.
Kidney function
Within normal limit renal function. Values outside those limits may be allowed at the discretion of the PI, if not clinically significant.
Liver function
Within normal limit hepatic function. Values outside those limits may be allowed at the discretion of the PI, if not clinically significant.
Within normal limit hematopoietic capacity, hepatic and renal function. Values outside those limits may be allowed at the discretion of the PI, if they are determined as not clinically significant.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Medical Dermatology Specialists · Phoenix, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify